Navigation Links
Drug combination acts against aggressive chronic lymphocytic leukemia
Date:12/10/2012

increase in leukemia cells in the blood due to release of CLL cells from the tissues (lymph glands) into the blood stream. Rituximab, a well-established antibody, was added to capture the CLL cells in the blood and thereby accelerate and improve response.

"When we looked at how well the high-risk patients were doing on ibrutinib - even though it was a small number - we saw a great opportunity to find out if combining the two drugs would have a positive impact on these patients," Burger said.

Combination tolerated well

Forty patients with high-risk CLL were enrolled in the study earlier this year. They received:

  • Daily oral doses of 420 mg ibrutinib throughout treatment
  • Weekly infusions of rituximab (375 mg/m2) weeks one through four
  • Monthly rituximab infusions for the next five months

At a median follow up of four months, 38 patients remained on ibrutinib therapy without disease progression. One patient died from an unrelated infectious complication, and one patient discontinued therapy due to oral ulcers.

Preliminary results: 85 percent response rate

Of 20 patients evaluated for early response at three months, 17 achieved partial remission for an overall response rate of 85%. Three achieved partial remission with persistent lymphocytosis.

Interestingly, lymphocytosis peaked earlier and the duration was shorter than with ibrutinib alone.

Treatment was well tolerated, with 13 cases of grade 3 or grade 4 toxicities, including neutropenia, fatigue, pneumonia, insomnia and bone aches. Most side effects were unrelated and transient. Many patients reported improved overall health and quality of life after three cycles of treatment.

"Although this study has a short follow-up time, we are encouraged by the fact that the vast majority of patients are responding and are able to continue on treatment, Burger said.

Development of ibrutinib for CLL
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
2. Combination treatment may improve survival of breast cancer patients with brain metastases
3. Drug combination against NRAS-mutant melanoma discovered
4. Combination peptide therapies might offer more effective, less toxic cancer treatment
5. DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination
6. BUSM in vitro study identifies potential combination therapy for breast cancer
7. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
8. Discovery suggests new combination therapy strategy for basal-like breast cancers
9. Cancer vaccine combination therapy shows survival benefit in breast cancer
10. Combination of 2 drugs reverses liver tumors
11. Immunotherapy for elderly cancer patients finds new promise in drug combination
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug combination acts against aggressive chronic lymphocytic leukemia
(Date:6/30/2015)... ... June 30, 2015 , ... The American Psychiatric Nurses ... Disney’s Coronado Springs Resort in Lake Buena Vista, Florida, and will offer more ... event for psychiatric-mental health nursing draws more than 1,500 health care professionals from ...
(Date:6/30/2015)... ... 30, 2015 , ... Medflow, the leader in the ophthalmic ... records system from the company exclusively dedicated to helping eye care professionals for ... state-of-the-art solution combining modern cloud technology with Medflow’s proven expertise in the eye ...
(Date:6/30/2015)... ... 2015 , ... Scott Purdy, the spokesperson for Dephinitive Systems LLC, announces today ... that the XO stands for eXtra Operability (XO) which was chosen to reflect the ... Revenue Cycle. , Provider XO, based in Cleveland OH, is part of the ...
(Date:6/29/2015)... ... June 30, 2015 , ... ... Richards as a 2015-2016 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting more than ...
(Date:6/29/2015)... ... 2015 , ... Aespala Medspa and Plastic Surgery is proud to introduce the ... , Dr. Dreyfuss received his medical degree from Emory University in Atlanta before completing ... Surgery Fellowship at the University of Chicago. He has taught and practiced medicine in ...
Breaking Medicine News(10 mins):Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 2Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 3Health News:Medflow Launches MEDFLOW 2.0 EHR – The Cloud-Based Ophthalmology EHR 2Health News:Dephinitive Systems Is Getting a New Name 2Health News:National Association of Professional Women Inducts Melanie Richards, DMD, of Powdersville Pediatric Dentistry, Into its VIP Woman of the Year Circle 2Health News:Aespala Medspa and Plastic Surgery Welcomes New Plastic Surgeon to Oak Brook, IL Office 2Health News:Aespala Medspa and Plastic Surgery Welcomes New Plastic Surgeon to Oak Brook, IL Office 3
... , MONDAY, May 16 (HealthDay News) -- When general doctors ... lesion, it,s more often another lesion that turns out to ... non-dermatologists might benefit from increased education on skin cancer detection, ... see the very high number of incidentally detected skin cancers," ...
... help prevent a serious complication associated with a contrast agent ... in the July issue of Radiology . ... (GBCA) has been linked to the development of nephrogenic systemic ... kidney disease. But since 2008, restrictive GBCA administration guidelines implemented ...
... new test for prostate cancer that measures levels of prostate ... in the blood of men with the disease was more ... today, according to a study by researchers at UCLA,s Jonsson ... also reduced the rate of false-positives, tests that indicate the ...
... 16 (HealthDay News) -- Asthma patients who delay seeking ... worse outcomes, including hospitalization. That,s the finding of ... New York City emergency departments. They were asked about ... at self-management before they decided to go to the ...
... bioengineering students have modified a child-size training mannequin to ... patients can be spared further stress and pain. ... Intended for Training, as their senior design project at ... who have long recognized the need for students to ...
... is the fourth-most-common cancer in men and one of ... death. After initial diagnosis and surgery, patients must return ... time-consuming and uncomfortable bladder scan. Tumors recur in more ... Washington are proposing a more automated approach that could ...
Cached Medicine News:Health News:GPs Lack Accuracy in Spotting Skin Cancers: Study 2Health News:GPs Lack Accuracy in Spotting Skin Cancers: Study 3Health News:Contrast agent guidelines help prevent debilitating disorder 2Health News:New prostate cancer test more specific, sensitive than PSA test 2Health News:New prostate cancer test more specific, sensitive than PSA test 3Health News:Don't Delay Emergency Care When Asthma Flare-Ups Strike 2Health News:Child-size mannequin: Hands-on training spares real patients 2Health News:Child-size mannequin: Hands-on training spares real patients 3Health News:Digital imaging software to create a 'Google Earth' view of the bladder 2Health News:Digital imaging software to create a 'Google Earth' view of the bladder 3
(Date:6/29/2015)... VILLAGE, Nev. , June 29, 2015  PDL ... it has entered into a credit agreement with CareView ... with up to $40 million of secured debt financing. ... industry focused on patient care monitoring. Under ... to $40 million of debt financing in two tranches ...
(Date:6/29/2015)... NESS ZIONA, Israel , ... Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary ... M-001, BiondVax,s candidate for a universal influenza vaccine. In ... the ages of 50 to 65, followed by an ... 3 weeks later. M-001 was found to be safe ...
(Date:6/29/2015)... , June 29, 2015 DURECT ... James E. Brown , President and CEO, ... Conference on Wednesday, July 8 at 11:45 a.m. ... Le Parker Meridien Hotel in New York City.  ... may request a one-on-one meeting through the conference ...
Breaking Medicine Technology:PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2
... risk of,stroke by 34% in patient with atrial fibrillation or ... adequately treated by antithrombotic ... a,post-hoc analysis of the data from the ATHENA study were ... Society of Cardiology,congress 2008, in Munich, Germany. Previous results from ...
... in Subjects with ALS, RICHMOND, Calif., Sept. 3 ... that it has opened a Phase,2 clinical trial (SB-509-801) ... progressive, degenerative motor-neuron disease for which there,are limited treatment ... an injectable formulation of a plasmid,encoding a zinc finger ...
Cached Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5
Inquire...
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
... In vivo results may be affected by the ... scar tissue can impact the desired augment-ation 1 ... from patient to patient. Implant dimensions can be ... surgical scissors. All dimensions in centimeters. This device ...
... IQmark family elevates your ECG and Spirometry capabilities ... and efficient patient care. The IQmark Diagnostic PDA ... clinics and medical centers as well as for ... conjunction with the IQmark Digital ECG PDA and ...
Medicine Products: